Finnish Herantis Pharma has launched the EUR 8 million EU-funded HERMOD research project to support a Phase 2 study of the drug candidate HER-096 for Parkinson’s disease.
The study is expected to include approximately 100 patients at European clinics and evaluate efficacy, safety and tolerability.
An application for a clinical trial is planned for the fourth quarter of this year, with first dosing in the first half of 2027, subject to funding and regulatory approvals.
Karolinska University Hospital is coordinating the project.
